Researchers quantify presence of immunotherapy biomarkers in breast cancerHealioSAN ANTONIO — Although a minority of patients with invasive breast cancer expressed microsatellite instability, high tumor mutational load or PD-L1 expression, these biomar… Continue reading
Immunotherapy May Reverse Type 1 DiabetesSpecialty Pharmacy TimesResearchers recently cured type 1 diabetes (T1D) by infusing mice models with blood stem cells that are engineered to overproduce the PD-L1 protein, which is deficient in T1D, according t… Continue reading
FierceBiotech |
Gilead, Kite to Acquire Cell Design Labs for Up-to-$567M, Growing CAR–T Footprint
Genetic Engineering & Biotechnology News Gilead Sciences and its Kite cell therapy subsidiary have agreed to acquire Cell Design Labs for up to approximately $567 million, in a deal designed to grow the buyers’ footprint in chimeric antigen receptor T cell (CAR-T) and other cellular therapies … Gilead deepens CAR–T push with deal for Cell DesignBioPharma Dive Gilead makes bolt-on CAR–T buy after Kite dealFierceBiotech Gilead swoops in with $567M deal to buy CAR-T 2.0 player Cell …Endpoints News Xconomy –San Francisco Business Times –MIT Technology Review all 25 news articles » |
|
CAR:T – Has biology outpaced the ability to deliver?
pharmaphorum Adapter CAR Program Manager. “The use of universal T cells might be the right tool to overcome shortage? First trials are promising…There’s emerging of companies doing exciting work with using renewable master to develop pluripotent stem cell lines … |